focus -WSS

focus

author：focus 2025-10-02 19:15:28 - browse：53

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:

The Food and Drug Administration’s decision in June to grant conditional approval to a gene therapy for Duchenne muscular dystrophy was a watershed moment for the treatment of the neuromuscular disease, and a big win for its maker, Sarepta Therapeutics. Confirming the gene therapy’s benefit — and potentially broadening its use to include older boys — will be determined by a Phase 3 clinical trial that will read out later this quarter.

Pfizeris developing its own gene therapy for Duchenne in a fully enrolled Phase 3 study with final results expected in 2024. But before the verdict is revealed, Pfizer intends to conduct an interim analysis later this quarter. The most likely outcome of this early look will be a determination to continue the study to its completion. But surprises — including an early stop for overwhelming efficacy — can’t be ruled out.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Why don't Americans have at

focus

WSS

ALS treatment from Biogen, Ionis fails in study

Cherokee Nation medical school graduates its first class

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Juul documents reveal insider tactics on political lobbying

Cherokee Nation medical school graduates its first class

hotspot

focus

focus

Jerome Adams on the need for new antivirals for Covid

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

State Dept. review finds Biden bears some blame for Afghanistan failures

Report cites 'urgent' need to recruit more diverse clinical trial participants

Sports medicine is finally prioritizing gender equality

Boston hospital trains restaurant workers on naloxone for overdoses

Peter Hotez and the public health issue of online harassment

Bernie Sanders gets little from pharma CEOs on drug prices

Hepatitis C has a cure — but many Americans still lack access to it

WuXi Biologics execs register to lobby as Congress comes for the company

explore

Congress might make insulin pumps more accessible to the blind

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Boston hospital trains restaurant workers on naloxone for overdoses

Too many hospitalized Covid

Having children helps parents live longer, especially after age 80

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Wikipedia

focus

focus

entertainment